ECM
TEVA icon

Endurant Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Endurant Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-175,000
Closed -$1.32M – 56
2023
Q2 		$1.32M Buy
+175,000
New +$1.42M 1.15% 21

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Endurant Capital Management's TEVA Position: Q2 2023 in Review

Endurant Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 762,264 shares — an estimated $6.18M sold.

Endurant Capital Management first reported a position in TEVA in Q4 2014 and held it in 16 quarters. The position peaked at $21.7M in Q4 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Endurant Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Endurant Capital Management sold 762,264 Teva Pharmaceuticals shares in Q2 2023, an estimated $6.18M.
  • Endurant Capital Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 16 quarters.
  • Endurant Capital Management's Teva Pharmaceuticals position peaked at $21.7M in Q4 2015.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.